Burkholderia
Infections Market - Global Industry Insights, Trends, Outlook, and Opportunity
Analysis, 2018-2026
Burkholderia infections are
caused by Burkholderia cepacia. It is a gram negative bacillus found in aquatic
environment. It is a low virulent bacteria and is a frequent colonizer of
fluids used in the hospitals such as IV fluid, irrigation solution etc. B.
cepacia can cause health problems to some people such as patients suffering
from weakened immune system or chronic lung diseases. Burkholderia infection
symptom can vary widely in people, ranging from no symptoms to serious
respiratory infection. Based on recent genomic subtyping techniques, Burkholderia
infection can be transmitted from person to person. Patients with lung disease such as asthma,
CFTR, and COPD are at high risk of suffering from Burkholderia infection.
Burkholderia cepacia is resistant to multiple antibiotic such as aminoglycosides,
antipseudomonal third-generation cephalosporins and antipseudomonal
penicillins.
Increasing prevalence of lung
diseases is expected to fuel growth of the Burkholderia infections market. The
exact cause for asthma, cystic fibrosis is unknown, though the risk factors can
be transferred generation from generation. As per the report of British Lung
Foundation, in 2011, an estimated 1.2 million people are living with chronic
obstructive pulmonary disease (COPD) and has grown by 27% in the last decade in
the U.K. According to the U.S. Cystic Fibrosis Foundation, Europe accounted for
the highest number of reported cases of cystic fibrosis in 2012. The growing
cases of COPD, asthma and other lung diseases create high risk of burkholderia
infection creating an opportunity for manufacturers. Burkholderia infections
also cause complications such as soft tissue infections, urinary tract
infection and surgical wound infections. It creates an opportunity for the
manufacturers to focus on overall treatment. The increasing outbreaks of
burkholderia infection has created focus towards the need for proper treatment
procedure.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/153
Many organization and government
policies have included burkholderia infection as one of the severe infections
spread from healthcare facilities. Transmission of B. cepacia from contaminated
medicines and medical devices. In 2005, CDC notified several states cluster of
pneumonia and other infection caused by B. cepacia associated with contaminated
mouthwash. In October, 2016, Nurse Assist Inc, recalled its normal saline flush
IV syringes due to Burkholderia Cepacia bloodstream infection. FDA identified
this as Class I recall, one of the most serious types of recall which may cause
serious injuries or death. In 2004, Burkholderia Cepacia was linked to
nosocomial infection among Intensive Care Unit patient and was associated with
exposure to sublingual probes. The growing concerns related to contaminated
medicines and medical devices are expected to create opportunity for product
manufacturers in the burkholderia infections market. The effect of B. cepacia
on people varies person to person which leaves the infection with no specific
treatment. The unavailability of proper treatment creates hindrance to the
overall market. North America is expected to account for maximum share of the
global burkholderia infections market, owing to the better diagnostic
facilities, increasing awareness and government initiative for early diagnosis
and treatment of burkholderia infection. Europe is expected to be the second
most lucrative burkholderia infections market.
Burkholderia Infections Market is
Highly Fragmented
The market is highly fragmented
due to the presence of many emerging players. Major players involved in the
burkholderia infections market includes Novabiotics Ltd, iQur Ltd, Aridis
Pharmaceuticals LLC, NanoBio Corporation, SUN pharma and others.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/burkholderia-infections-market-153
Key Developments
Continuous research and
development activities are expected to facilitate growth of the burkholderia
infections market. For instance, in February 2019, the National Institutes of
Health (NIH) awarded a US$ 3.34 million grant to researchers at Case Western
Reserve University School of Medicine to research and develop a technique for
sensitizing Burkholderia multivorans, a common pathogen found in patients with
lung diseases, to antibiotics.
Increasing number of investments
by regulatory authorities, as well as private organisations to fund R&D
activities is driving the market growth. In August 2019, the Biomedical
Advanced Research and Development Authority (BARDA), announced a 2-year grant
of up to US $20.7 million to VenatoRx Pharmaceuticals, who will then
collaborate with BARDA’s Office of the Assistant Secretary for Preparedness and
Response (ASPR), and the Department of Defense’s Defense Threat Reduction
Agency (DTRA) to test the efficacy of VNRX-5133 compound in treating pathogens,
specifically, melioidosis-causing bacterium Burkholderia pseudomallei.
Moreover, in October 2018,
Synspira’s candidate therapy, SNSP113, received the orphan drug status from the
U.S. Food and Drug Administration (FDA) for treating bacterial infections such
as Burkholderia and non-tuberculous Mycobacteria in patients with cystic
fibrosis (CF).
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/153
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment